J M Michalski, J Moughan, J A Purdy, D W Bruner, M Amin, J P Bahary, H Lau, M Duclos, D Yee, G Morton, R T Dess, D E Doncals, M I Lock, H Lukka, B C Baumann, E Vigneault, Y Kwok, J Robertson, D L Schwartz, H M Sandler
PURPOSE/OBJECTIVE(S): NRG/RTOG 0126, a phase III trial for men with localized prostate cancer testing whether dose escalation to 79.2 Gy with 3DCRT/IMRT improved overall survival (OS). Long-term results of this trial are presented. MATERIALS/METHODS: Patients with clinical stage T1b-T2b and either Gleason Score (GS) 2-6 and 10 ≤ PSA < 20 or GS 7 and PSA < 15 were eligible and randomized to receive 79.2 Gy or 70.2 Gy. No previous or concurrent androgen withdrawal therapy was administered...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics